Introdução: Anormalidades nos supressores tumorais p14, p16 e p53 são relatadas em diversos tipos de câncer em humanos. Na carcinogênese ovariana, p16 e p53 foram extensivamente estudados, mas p14 foi analisado somente em carcinomas. Objetivo: O estudo visa determinar a expressão imuno-histoquímica de p14, p16 e p53 em tumores ovarianos epiteliais benignos, borderline e malignos. Método: Estudo transversal utilizando imuno-histoquímica em amostras de tumores epiteliais ovarianos emblocados em parafina do Hospital de Clínicas de Porto Alegre. Resultados: p14 foi positivo em 93% dos tumores benignos, 94% dos borderline e 60% dos malignos. A perda de expressão foi estatisticamente associada com carcinomas. p16 foi positivo em 94,6% dos carcinomas, 75% dos tumores borderline e 45,7% dos benignos. p53 foi positivo em 29,7%, 16,7% e 2,9% dos tumores malignos, borderline e benignos, respectivamente. Os subtipos de carcinoma não mostraram diferenças de expressão. Conclusão: Nosso estudo foi o primeiro a descrever a expressão de p14 em tumores benignos e borderline. Ela permanece estável nos benignos e borderline, enquanto os carcinomas exibem uma perda de expressão significativa. Isso pode indicar que anormalidades de p14 acontecem tardiamente na carcinogênese. As taxas de expressão de p16 e p53 foram semelhantes a estudos anteriores. Estudos futuros devem investigar anormalidades genéticas nas sequencias codificadoras de p14 e incluir todos os tipos de tumor epitelial ovariano. / Background: Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian carcinogenesis, p16 and p53 have been extensively studied, but p14 was only analyzed in carcinomas. Aim: This study seeks to determine p14, p16 and p53 immunohistochemical expression in benign, borderline and malignant ovarian epithelial tumors and correlate them with survival and clinical variables. Methods: Cross-sectional study utilizing immunohistochemical staining of p14, p16 and p53 in paraffin-embedded tissue samples from ovarian epithelial tumors obtained from Hospital de Clinicas de Porto Alegre. Results: p14 was positive in 93% of benign, 94% of borderline and 60% of malignant tumors. Loss of expression was statistically associated with carcinomas. p16 was positive in 94.6% of carcinomas, 75% of borderline and 45.7% of benign tumors. p53 was positive in 29.7%, 16.7% and 2.9% of malignant, borderline and benign tumors, respectively. Carcinoma subtypes showed no difference in expression. Conclusions: To our knowledge, this is the first description of p14 expression in benign and borderline tumors. It remains stable in benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate p14 abnormalities occur later in carcinogenesis. p16 and p53 expression rates show similar results to previous reports. Future studies should investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors.

Introdução: Anormalidades nos supressores tumorais p14, p16 e p53 são relatadas em diversos tipos de câncer em humanos. Na carcinogênese ovariana, p16 e p53 foram extensivamente estudados, mas p14 foi analisado somente em carcinomas. Objetivo: O estudo visa determinar a expressão imuno-histoquímica de p14, p16 e p53 em tumores ovarianos epiteliais benignos, borderline e malignos. Método: Estudo transversal utilizando imuno-histoquímica em amostras de tumores epiteliais ovarianos emblocados em parafina do Hospital de Clínicas de Porto Alegre. Resultados: p14 foi positivo em 93% dos tumores benignos, 94% dos borderline e 60% dos malignos. A perda de expressão foi estatisticamente associada com carcinomas. p16 foi positivo em 94,6% dos carcinomas, 75% dos tumores borderline e 45,7% dos benignos. p53 foi positivo em 29,7%, 16,7% e 2,9% dos tumores malignos, borderline e benignos, respectivamente. Os subtipos de carcinoma não mostraram diferenças de expressão. Conclusão: Nosso estudo foi o primeiro a descrever a expressão de p14 em tumores benignos e borderline. Ela permanece estável nos benignos e borderline, enquanto os carcinomas exibem uma perda de expressão significativa. Isso pode indicar que anormalidades de p14 acontecem tardiamente na carcinogênese. As taxas de expressão de p16 e p53 foram semelhantes a estudos anteriores. Estudos futuros devem investigar anormalidades genéticas nas sequencias codificadoras de p14 e incluir todos os tipos de tumor epitelial ovariano. / Background: Abnormalities in tumor suppressors p14, p16 and p53 are reported in several human cancers. In ovarian carcinogenesis, p16 and p53 have been extensively studied, but p14 was only analyzed in carcinomas. Aim: This study seeks to determine p14, p16 and p53 immunohistochemical expression in benign, borderline and malignant ovarian epithelial tumors and correlate them with survival and clinical variables. Methods: Cross-sectional study utilizing immunohistochemical staining of p14, p16 and p53 in paraffin-embedded tissue samples from ovarian epithelial tumors obtained from Hospital de Clinicas de Porto Alegre. Results: p14 was positive in 93% of benign, 94% of borderline and 60% of malignant tumors. Loss of expression was statistically associated with carcinomas. p16 was positive in 94.6% of carcinomas, 75% of borderline and 45.7% of benign tumors. p53 was positive in 29.7%, 16.7% and 2.9% of malignant, borderline and benign tumors, respectively. Carcinoma subtypes showed no difference in expression. Conclusions: To our knowledge, this is the first description of p14 expression in benign and borderline tumors. It remains stable in benign and borderline tumors, while carcinomas show a significant absence of staining. This may indicate p14 abnormalities occur later in carcinogenesis. p16 and p53 expression rates show similar results to previous reports. Future studies should investigate genetic abnormalities in p14 coding sequences and include all types of ovarian epithelial tumors.

Le virus des nervures jaunes et nécrotiques de la betterave (Beet necrotic yellow vein virus, BNYVV) est l’agent infectieux responsable de la rhizomanie de la betterave sucrière, une maladie caractérisée par une prolifération anarchique du chevelu racinaire. Le Beet soil-borne mosaic virus (BSBMV) appartient également au genre Benyvirus mais n’est retrouvé qu’en Amérique du Nord. Ce virus, identifié pour la première fois au Texas, est morphologiquement et génétiquement semblable au BNYVV mais sérologiquement éloigné. Compte tenu des différences moléculaires existant, le BSBMV et BNYVV correspondent à deux espèces virales distinctes. Mon projet de thèse a consisté à étudier les interactions moléculaires entre le BNYVV et le BSBMV et rechercher les mécanismes impliqués dans la pathogénicité de ces deux virus. Des clones complets cDNA infectieux du BNYVV étaient disponibles, tout comme ceux de BSBMV. Compte tenu de l’aspect versatile de l’obtention de transcrits infectieux de ces différents clones, j’ai entrepris de produire des clones cDNA de chacun des ARN viraux sous contrôle d’un promoteur constitutive végétal pour initier l’infection par agroinfiltration. Les plantes hôtes Chenopodium quinoa et Nicotiana benthamiana ont été inoculées par des transcrits et agroinfiltrées pour initier l’infection virale et étudier l’interaction entre les ARN génomiques 1 et 2 des deux virus et étudier les propriétés de constructions chimères. En parallèle à ce travail, j’ai réalisé la caractérisation du suppresseur de RNA silencing du BSBMV en le comparant à celui du BNYVV. / The genus Benyvirus includes the most important and widespread sugar beet viruses transmitted through the soil by the plasmodiophorid Polymyxa betae. In particular Beet necrotic yellow vein virus (BNYVV), the leading infectious agent that affects sugar beet, causes an abnormal rootlet proliferation known as rhizomania. Beet soil-borne mosaic virus (BSBMV) is widely distributed in the United States and, up to date has not been reported in others countries. My PhD project aims to investigate molecular interactions between BNYVV and BSBMV and the mechanisms involved in the pathogenesis of these viruses.BNYVV full-length infectious cDNA clones were available as well as full-length cDNA clones of BSBMV RNA-1, -2, -3 and -4. Handling of these cDNA clones in order to produce in vitro infectious transcripts need sensitive and expensive steps, so Ideveloped agroclones of BNYVV and BSBMV RNAs, as well as viral replicons allowing the expression of different proteins.Chenopodium quinoa and Nicotiana benthamiana plants have been infected with in vitro transcripts and agroclones to investigate the interaction between BNYVV and BSBMV RNA-1 and -2 and the behavior of artificial viral chimeras. Simultaneously I characterized BSBMV p14 and demonstrated that it is a suppressor of posttranscriptional gene silencing sharing common features with BNYVV p14.

Today, development of accurate early diagnosis of cancers thus became the number one challenge of medicine during the 21st century as the current techniques relies on imaging methods that suffer from low sensitivity and misdiagnosis.For these reasons, in this work, we aimed at developing a no-wash colorimetric biosensor for the detection of the oncoprotein Mdm2. Indeed, abnormal levels of Mdm2 could be related to the early formation of tumors.This thesis is devoted to the conception of a no-wash colorimetric biosensor for the detection of the oncoprotein Mdm2. This work can be divided in four parts:(i) The detection strategy and the design of the recognition elements (Chapter I).(ii) The conjugation of gold nanoparticles with the recognition elements (Chapter II, III, IV, V and VI).(iii) The modification of the metallic core of the nanoparticles (Chapter VII).(iv) The use of the optimized biosensor for the detection of Mdm2 (Chapter VIII).In the first part, we investigated the sensing strategy. An aggregation-based assay with plasmonic nanoparticles was selected, as the detection signal is a change of color of the suspension that can be observed to the naked eye or by UV-Vis spectroscopy. We designed the recognition elements, two peptide aptamers coming from endogenous proteins p53 and p14, and we grafted them separately on two batches of gold nanoparticles (AuNPs) via thiol end-groups. We used these latter for the detection of various concentrations of Mdm2 in buffer using our dual-trapping strategy with these two batches of functionalized AuNPs. We demonstrated that both peptides are able to interact with Mdm2 even after grafting onto the particles and that this detection strategy is highly specific. However, this first sensor presented some drawbacks, such as a poor colloidal stability of the AuNPs and a limited dynamic range.With the aim to encompass these issues we investigated, in the second part of this thesis, alternative strategies to conjugate the peptides to the particles. We investigated the functionalization of the particles with stabilizing ligands such as thiolated poly(ethyleneglycol) (HS-PEG). We first studied their simultaneous grafting with the peptides on the AuNPs. We observed that grafting HS-PEGs and peptides side-by-side allowed to control the density of peptides conjugated to the AuNPS and increased drastically the stability of the particles. However, the detection of Mdm2 was strongly hindered by the presence of PEG on the particles carrying the p14 peptide. In a second step, we investigated the conjugation of peptides on the top of a PEG layer carrying functional groups (HS-PEG-X where X is a carboxylate or an alkyne). AuNPs were first functionalized with mixtures of HS-PEG and HS-PEG-X, and the peptides were conjugated to the functional groups via amide bond formation or CuAAC coupling in a second step. However, we noticed that it was not possible to control the composition of the mixed layer of PEGs and thus the peptide grafting density.Due to the lack of recognized protocols in the literature for (i) the determination of the chemical and colloidal stabilities of AuNPs and (ii) the determination of the proportion of different ligands in the organic coating of the particles, we developed two interesting tools. The first one was a convenient method allowing to evaluate by UV-Vis spectroscopy the efficiency of the citrate exchange process using thiol-, alkyne- or diazonium-ligands from gold nanoparticles synthesized via a Turkevich method. The second protocol was a method allowing to quantify the proportion of two HS-PEGs ligands grafted in mixtures onto gold nanoparticles via 1H NMR spectroscopy.As we couldn’t find conditions in which the proportion of multiple thiolated ligands can be controlled on AuNPs, we decided to investigate another functionalization strategy based on the use of calix4arene-diazonium salts.We first studied the grafting on AuNPs of calixarenes bearing four PEG chains at the level of their small rim, one ended by a carboxylic acid and three by a methoxy group. The calixarene layer allowed to obtain AuNPs covered by a very dense PEG shell (with more PEG chains/nm2 that what was obtained previously with thiol anchoring). In addition to that, this PEG shell was strongly anchored to the AuNPs, conferring them a very high colloidal and chemical robustness. We then combined the grafting of this calixarene with the grafting of another non-functional calixarene, bearing four PEG chains ended by a methoxy group, and we quantified the conjugation capacity of such particles by amide bond formation. We demonstrated that this strategy allows to (i) increase drastically the stability of the AuNPs and (ii) control the proportion of peptide conjugated at their surface. Finally, we showed that calixarene-coated AuNPs to which to the p53 and p14 peptides have been conjugated could be used to detect Mdm2.With the evidence that the peptide conjugation density could be controlled using calixarene-coated AuNPs, we investigated the simultaneous grafting of two functional calixarenes on particles: one bearing four carboxylic acids groups and one bearing four PEG chains ended by alkyne groups. We optimized the grafting of these calixarenes in mixed layers on the AuNPs as well as their conjugation. We demonstrated that the grafting of two functional calixarenes led to the production of bi-functional AuNPs, capable of conjugation with two molecules via two distinct chemistries.In the third part, we optimized the composition of the metallic core of the biosensor. As it is well known that silver nanoparticles express better optical properties than gold nanoparticles of the same size, we aimed to incorporate silver nanoparticles (AgNPs) in the biosensor. This was a true challenge due to the intrinsic low chemical stability of silver nanoparticles that greatly limits their use in IVD. For this purpose, we developed an innovative in situ synthesis of silver nanoparticles in the presence of the calixarene-diazonium salts. After optimization of the synthesis, we observed that calixarenes bearing four carboxylic acids groups at the level of their small rim allowed the production of ultra-stable silver nanoparticles to which biomolecules can easily be conjugated. This in situ synthesis procedure even allowed us to produce alloy nanoparticles, with metallic cores whose composition could easily be tuned from pure silver to silver/gold alloys or pure gold. With this synthesis, the composition of the organic layer could also be easily tuned by using mixtures of calixarenes-diazonium salts.Finally, in the last part, we investigated the detection of Mdm2 with the optimized version of the biosensor, i.e. silver nanoparticles coated by a calixarene layer to which the p53 and p14 peptides were conjugated. With this novel class of nanoparticles, we could encompass the two initial drawbacks of the initial sensor. First, we were able to detect Mdm2 with a wider detection range and a lower limit. Secondly, the particles were sufficiently stable and robust to be dispersed in physiological fluids and we could detect Mdm2 in human serum without interference. / Doctorat en Sciences de l'ingénieur et technologie / info:eu-repo/semantics/nonPublished